Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 4:12:2007-2014.
doi: 10.2147/PPA.S170054. eCollection 2018.

Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice

Peter C Taylor  1 , Rieke Alten  2 , Juan J Gomez Reino  3 , Roberto Caporali  4 , Philippe Bertin  5 , Emma Sullivan  6 , Robert Wood  6 , James Piercy  6 , Radu Vasilescu  7 , Dean Spurden  8 , Jose Alvir  9 , Miriam Tarallo  10
Affiliations

Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice

Peter C Taylor et al. Patient Prefer Adherence. .

Abstract

Objective: The aim of this study was to identify factors that influence treatment adjustments and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in European practices.

Methods: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Programme. Treatment patterns and clinical characteristics were investigated in patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) vs non-bDMARDs. For the T2T analysis, patients were subdivided into two subsets (RA diagnosis <2 or ≥2 years) and compared according to the approach used (no target = no T2T approach; pragmatic = target different from remission; and aspirational = target set as remission).

Results: Data from 2,536 patients were analyzed (mean age: 52.76 years and mean time since RA diagnosis: 6.05 years). Of the 1,438 patients eligible to receive bDMARDs, 55% did not receive them. Initiation of bDMARDs in a bDMARD-naïve patient was prompted by worsening of the disease. In the RA diagnosis <2 years subset, a T2T approach was not adopted in 58% of the patients, whereas 8% and 34% adopted a pragmatic and aspirational approach, respectively. In the RA diagnosis ≥2 years subset, 45%, 19%, and 36% of the patients adopted a no target, pragmatic, and aspirational approach, respectively. Physician satisfaction with RA control was lower in the RA diagnosis <2 years subset than in the RA diagnosis ≥2 years subset (65% vs 77% satisfied, respectively; P<0.0001).

Conclusion: This analysis shows that the use of bDMARDs remains suboptimal and that a T2T strategy is not universally adopted.

Keywords: disease-modifying antirheumatic drugs; rheumatoid arthritis; treat-to-target.

PubMed Disclaimer

Conflict of interest statement

Disclosure PCT has received fees from AbbVie, Bristol-Myers Squibb, Janssen, Lilly, Merck, Pfizer, Sandoz, Biogen, and UCB Pharma. RA has received fees from AbbVie, Bristol-Myers Squibb, Janssen, Lilly, Merck, Pfizer, Sandoz, Biogen, and UCB Pharma. JJGR has received fees from AbbVie, Biogen, Bristol-Myers Squibb, Hospira, Janssen, Merck, Pfizer, Regeneron, and UCB Pharma. RC has received fees from AbbVie, MSD, Pfizer, Roche, and UCB Pharma. PB has received fees from MSD, Pfizer, Reckitt Benckiser, and Roche. ES, RW, and JP are employees of Adelphi Real World and were contracted by Pfizer to provide data, input into design of data collection, and statistical support for the development of this study. This study was spon sored by Pfizer. Adelphi Real World was contracted by Pfizer to conduct the survey and provide data, input into design of data collection, and statistical support for the development of this study. Preliminary data from this study were presented as posters at the British Society for Rheumatology (BSR) Annual Meeting, April 26–28, 2016, Glasgow, Scotland, and at the Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP); November 6–11, 2015; San Francisco, CA, USA. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Factors influencing bDMARD treatment start. Notes: Physicians could respond with more than one reason. (A) Physician-reported reasons for the choice of first-line bDMARD. Overall N=629. (B) Physician-reported reasons for switching previous bDMARD for current/most recent bDMARD. Overall N=297; physicians could only provide a reason for switching in the 297 patients who received two or more bDMARDs. (C) Physician-reported reasons that would prompt initiation of bDMARD therapy in bDMARD-naïve patients. Overall N=495. Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; DAS, disease activity score.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Smolen JS, Aletaha D, Mcinnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. - PubMed
    1. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68(1):1–25. - PubMed
    1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. - PubMed
    1. Espinoza F, Fabre S, Pers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):107–118. - PMC - PubMed
    1. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057. - PMC - PubMed